High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer.

FoxP1 has been reported to be expressed in several types of human malignant tumors, and has been associated with metastasis and patient prognosis. Quantitative real-time polymerase chain reaction (PCR) and immunohistochemical analysis with tissue microarray were used to characterize the expression of FoxP1 in non-small cell lung cancer (NSCLC). It was revealed that the expression of FoxP1 messenger RNA (mRNA) and protein was significantly higher in NSCLC tissue than in corresponding peritumoral tissue (P = .013 and P < .001, respectively). The expression of FoxP1 protein in NSCLC was related to gender, histologic type, and 5-year survival rate (all P < .05). Finally, we evaluated the prognostic significance of the expression of FoxP1 in a group of patients. Kaplan-Meier survival and Cox regression analyses showed that low expression of FoxP1 (P < .001) and later stage grouping by TNM (P = .022) were independent factors predicting poor prognosis for NSCLC.

[1]  S. Fox,et al.  Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas , 2008, Breast Cancer Research and Treatment.

[2]  A. Banham,et al.  FOXP1: a potential therapeutic target in cancer , 2007, Expert opinion on therapeutic targets.

[3]  Zhenqing Feng,et al.  The patterns and expression of KDR in normal tissues of human internal organs , 2011, Journal of Molecular Histology.

[4]  Shanru Li,et al.  Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. , 2010, Genes & development.

[5]  S. Fox,et al.  Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor α and Improved Survival in Primary Human Breast Carcinomas , 2004, Clinical Cancer Research.

[6]  C Fidler,et al.  The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. , 2001, Cancer research.

[7]  P. Marynen,et al.  FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations , 2005, Leukemia.

[8]  Huiyun Gao,et al.  Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function. , 2008, Blood.

[9]  M. Lu,et al.  Foxp2 and Foxp1 cooperatively regulate lung and esophagus development , 2007, Development.

[10]  P. Tucker,et al.  DNA-binding properties and secondary structural model of the hepatocyte nuclear factor 3/fork head domain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Harris,et al.  Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1α expression , 2006, Modern Pathology.

[12]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[13]  A. Tzankov,et al.  New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma , 2008, Journal of Clinical Pathology.

[14]  J. Nardone,et al.  Foxp1 is an essential transcriptional regulator of B cell development , 2006, Nature Immunology.

[15]  S. Fox,et al.  Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia , 2007, The Prostate.

[16]  E. Haralambieva,et al.  FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B‐cell lymphomas with non‐germinal centre phenotype, independent of gains and structural aberrations at 3p14.1 , 2010, Histopathology.

[17]  J. Brahmer,et al.  Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer , 2011, Cancer investigation.

[18]  T. Mitsudomi.  Advances in target therapy for lung cancer. , 2010, Japanese journal of clinical oncology.

[19]  P. Goldstraw.  The 7th Edition of TNM in Lung Cancer: what now? , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  M. Wirth,et al.  Expression of the Forkhead Transcription Factor FOXP1 is Associated with Tumor Grade and Ki67 Expression in Clear Cell Renal Cell Carcinoma , 2011, Cancer investigation.

[21]  Y. Hayashizaki,et al.  FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. , 2008, Biochemical and biophysical research communications.

[22]  J. Orenstein,et al.  Revolution in lung cancer: new challenges for the surgical pathologist. , 2012, Archives of pathology & laboratory medicine.

[23]  R. Souhami,et al.  Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Kutok,et al.  Complexity Made Simple in Diffuse Large B-Cell Lymphoma , 2009, Clinical Cancer Research.

[25]  Michael R. Green,et al.  Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFkappaB activity in Follicular Lymphoma. , 2009, Leukemia research.

[26]  Feng Zhang,et al.  Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma , 2011, Journal of Clinical Pathology.